auto-fix: strip 2 broken wiki links

Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.

domains/health/federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings.md

@@ -39,6 +39,12 @@ The GLP-1 case is particularly stark because the clinical evidence is robust (ca
 
 The claim that budget scoring "systematically" undervalues prevention requires evidence beyond a single case. However, the GLP-1 divergence is consistent with known CBO methodology (10-year window, conservative assumptions) and parallels similar scoring challenges for other preventive interventions (vaccines, screening programs). The structural bias is well-documented in health policy literature, though this source provides the most dramatic single-case illustration.
 
+
+### Additional Evidence (confirm)
+*Source: [[2024-11-01-aspe-medicare-anti-obesity-medication-coverage]] | Added: 2026-03-16*
+
+CBO scored Medicare GLP-1 coverage at $35B additional spending over 2026-2034, while ASPE clinical economics analysis found net savings of $715M over 10 years from the same policy. The $35.7B divergence stems from CBO's conservative assumptions about uptake rates and limited counting of downstream savings (avoided hospitalizations, disease progression) within the 10-year budget window. ASPE's model includes 38,950 cardiovascular events avoided and 6,180 deaths avoided, which generate healthcare cost offsets that CBO methodology structurally undercounts.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

@@ -30,6 +30,12 @@ For value-based care models and capitated payers, this multi-organ protection cr
 - Nature Medicine: additive benefits with SGLT2 inhibitors
 - First GLP-1 to receive FDA indication for CKD in T2D patients
 
+
+### Additional Evidence (confirm)
+*Source: [[2024-11-01-aspe-medicare-anti-obesity-medication-coverage]] | Added: 2026-03-16*
+
+ASPE's broad semaglutide access scenario projects 38,950 cardiovascular events avoided and 6,180 deaths avoided over 10 years among Medicare beneficiaries. The eligibility criteria require comorbidities (CVD history, heart failure, CKD, prediabetes) rather than BMI alone, targeting the population where multi-organ protection creates the highest clinical value. Approximately 10% of Medicare beneficiaries would be eligible under these criteria.
+
 ---
 
 Relevant Notes:

entities/internet-finance/futardio.md

@@ -51,6 +51,8 @@ MetaDAO's token launch platform. Implements "unruggable ICOs" — permissionless
 - **2024-06-14** — [[futardio-fund-rug-bounty-program]] passed: Approved $5K USDC funding for RugBounty.xyz platform development to incentivize community recovery from rug pulls
 - **2024-08-28** — MetaDAO proposal to develop futardio as memecoin launchpad with futarchy governance failed. Proposal would have allocated $100k grant over 6 months to development team. Key features: percentage of each new token supply allocated to futarchy DAO, points-to-token conversion within 180 days, revenue distribution to $FUTA holders, immutable deployment on IPFS/Arweave. Proposal rejected by market, suggesting reputational risks outweighed adoption benefits.
 - **2025-11-14** — Solomon launch: $8M raised (12.9x oversubscribed, $102.9M committed) for composable yield-bearing stablecoin
+- **2024-08-28** — MetaDAO proposal to develop futardio (memecoin launchpad with futarchy governance) failed. Proposal included $100k grant over 6 months, Q3 launch target, and plan for immutable hyperstructure with $FUTA token distributing platform revenue to users and MetaDAO. Proposal explicitly framed memecoins as ideal futarchy use-case due to single objective function (token price).
+- **2024-08-28** — MetaDAO proposal to develop futardio failed. Proposal would have allocated $100k grant over 6 months to build memecoin launchpad where percentage of each token supply goes to futarchy DAO, with points-to-token bootstrapping mechanism ($FUTA) and immutable hyperstructure deployment on IPFS/Arweave. Proposal explicitly framed as test of whether memecoin association would help or hurt futarchy adoption.
 ## Competitive Position
 - **Unique mechanism**: Only launch platform with futarchy-governed accountability and treasury return guarantees
 - **vs pump.fun**: pump.fun is memecoin launch (zero accountability, pure speculation). Futardio is ownership coin launch (futarchy governance, treasury enforcement). Different categories despite both being "launch platforms."

entities/internet-finance/metadao.md

@@ -58,13 +58,14 @@ The futarchy governance protocol on Solana. Implements decision markets through
 - **2024-03-02** — [[metadao-increase-meta-liquidity-dutch-auction]] passed: completed Dutch auction and liquidity provision, moving all protocol-owned liquidity to Meteora 1% fee pool
 - **2025-01-27** — [[metadao-otc-trade-theia-2]] proposed: Theia offers $500K for 370.370 META at 14% premium with 12-month vesting
 - **2025-01-30** — [[metadao-otc-trade-theia-2]] passed: Theia acquires 370.370 META tokens for $500,000 USDC
-- **2023-11-18** — [[metadao-develop-lst-vote-market]] proposed: first product development proposal requesting 3,000 META to build Votium-style validator bribe platform for MNDE/mSOL holders
-- **2023-11-29** — [[metadao-develop-lst-vote-market]] passed: approved LST Vote Market development with projected $10.5M enterprise value addition
+- **2023-11-18** — metadao-develop-lst-vote-market proposed: first product development proposal requesting 3,000 META to build Votium-style validator bribe platform for MNDE/mSOL holders
+- **2023-11-29** — metadao-develop-lst-vote-market passed: approved LST Vote Market development with projected $10.5M enterprise value addition
 - **2023-12-03** — Proposed Autocrat v0.1 migration with configurable proposal slots and 3-day default duration
 - **2023-12-13** — Completed Autocrat v0.1 migration, moving 990,000 META, 10,025 USDC, and 5.5 SOL to new program despite unverifiable build
 - **2024-01-24** — Proposed AMM program to replace CLOB markets, addressing liquidity fragmentation and state rent costs (Proposal CF9QUBS251FnNGZHLJ4WbB2CVRi5BtqJbCqMi47NX1PG)
 - **2024-01-29** — AMM proposal passed with 400 META on approval and 800 META on completion budget
 - **2024-08-31** — Passed proposal to enter services agreement with Organization Technology LLC, creating US entity vehicle for paying contributors with $1.378M annualized burn rate. Entity owns no IP (all owned by MetaDAO LLC) and cannot encumber MetaDAO LLC. Agreement cancellable with 30-day notice or immediately for material breach.
+- **2024-10-22** — Proposal to hire Advaith Sekharan as founding engineer passed with $180k/year salary and 237 META tokens (1% of supply) with performance-based unlocks starting at $500M market cap and full unlock at $5B, 4-year vest beginning November 2024, 8-month clawback period
 ## Key Decisions
 | Date | Proposal | Proposer | Category | Outcome |
 |------|----------|----------|----------|---------|

inbox/archive/2024-11-01-aspe-medicare-anti-obesity-medication-coverage.md

@@ -7,9 +7,13 @@ date: 2024-11-01
 domain: health
 secondary_domains: [internet-finance]
 format: policy
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, medicare, obesity, budget-impact, CBO, federal-spending]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -45,3 +49,11 @@ WHY ARCHIVED: The CBO vs. ASPE divergence reveals a systematic bias in how preve
 EXTRACTION HINT: Focus on the methodological divergence as evidence of structural misalignment in policy evaluation, not just the GLP-1 budget numbers
 
 flagged_for_leo: ["Budget scoring methodology systematically disadvantages prevention — this is a cross-domain structural problem affecting all preventive health investments"]
+
+
+## Key Facts
+- CBO estimates Medicare GLP-1 coverage would increase federal spending by $35 billion over 2026-2034
+- ASPE estimates net savings of $715 million over 10 years (range: $412M to $1.04B across scenarios)
+- Annual Part D cost increase projected at $3.1-6.1 billion
+- Approximately 10% of Medicare beneficiaries would be eligible under proposed comorbidity-based criteria
+- Broad semaglutide access projected to avoid 38,950 CV events and 6,180 deaths over 10 years